title: Pharmaceutical approval update.
abstract: Belinostat (Beleodaq) for peripheral T-cell lymphoma; C1-esterase inhibitor (Ruconest) for acute attacks in hereditary angioedema; and tedizolid phosphate (Sivextro) for acute bacterial skin and skin structure infections.
authors.forename: Marvin M
authors.initials: MM
authors.lastname: Goldenberg